ATTR-CM Treatment: Symptoms, Diagnosis, and Discoveries
By: Katie Wu, Emily Noronha, Claire Baum, Cait Williamson PhD
Posted: September 25, 2026
Transthyretin amyloid cardiomyopathy, or ATTR-CM, is a heart condition that is frequently mistaken for other common forms of heart failure. Many patients live with it for years before a formal diagnosis. This guide covers what ATTR-CM is, why it's so easy to miss, and how ATTR-CM treatment has gone from a single drug to a highly complex field in just a few years.
What is ATTR-CM?
ATTR-CM is a progressive disease in which a protein called transthyretin (TTR), normally made in the liver to help carry thyroid hormone and vitamin A through the bloodstream, becomes unstable and misfolds. The misfolded protein clumps together into amyloid fibrils that deposit in the heart muscle, causing the walls of the heart to thicken and stiffen. Over time, this makes it harder for the heart to relax, fill with blood, and eventually pump effectively, a pattern known as restrictive cardiomyopathy.
There are two forms of the disease. Wild-type ATTR-CM (wATTR-CM) is an aging-related condition, unconnected to any inherited mutation, that mostly affects men in their 70s and 80s. Hereditary ATTR-CM (hATTR-CM) is caused by a mutation in the TTR gene, tends to show up earlier in life, and can also affect the nerves. In the United States, the most common disease-causing variant, Val122Ile, is a significant and often under-recognized cause of heart failure that disproportionately affects Black Americans.
ATTR-CM is considered rare, but likely far less rare than once believed. Researchers estimate around 100,000 people in the U.S. are living with it, yet only a small fraction have ever been diagnosed. Autopsy studies suggest amyloid deposits are present in a meaningful share of elderly hearts, hinting at a much larger undiagnosed population than current numbers capture.
ATTR-CM symptoms: what it looks like day to day
Because ATTR-CM mimics ordinary heart failure, symptoms are frequently attributed to other conditions. Patients and their doctors often describe:
- Shortness of breath with minimal activity or at rest
- Fatigue and reduced exercise tolerance that gradually worsens
- Swelling in the legs, ankles, or abdomen from fluid retention
- Carpal tunnel syndrome, sometimes years before any heart symptoms appear
- Lightheadedness, fainting, or an irregular heartbeat, often atrial fibrillation
A cluster of non-cardiac clues can also point toward ATTR-CM before a cardiologist is ever involved: bilateral carpal tunnel syndrome, spinal stenosis, and biceps tendon rupture have all been flagged as early warning signs that can precede heart symptoms by years.
Why ATTR-CM gets mistaken for something else
ATTR-CM is most often confused with hypertensive heart disease or hypertrophic cardiomyopathy, since all three can produce a thickened left ventricle on an echocardiogram. It also overlaps with the far more common causes of heart failure with preserved ejection fraction seen in older adults, which is part of why it's easy for clinicians to attribute symptoms to aging or routine heart failure rather than dig further.
Getting to the right diagnosis usually involves a cardiologist, imaging, and blood tests to rule out a related condition called light-chain (AL) amyloidosis. Bone scintigraphy, a nuclear medicine scan that binds selectively to amyloid deposits in the heart, has become central to non-invasive diagnosis and, combined with blood and urine tests to exclude AL amyloidosis, can confirm ATTR-CM without a biopsy in many cases. Genetic testing is then used to determine whether the disease is wild-type or hereditary. Even with these tools available, diagnosis is frequently delayed, and misdiagnosis remains common enough that disease awareness campaigns continue to target both cardiologists and primary care physicians.
ATTR-CM vs. ATTR-PN: when amyloid affects the nerves
ATTR-CM is closely related to transthyretin amyloid polyneuropathy, or ATTR-PN. Both are caused by the same misfolded TTR protein, but here the amyloid builds up mainly in the peripheral and autonomic nerves rather than the heart. ATTR-PN is almost always hereditary, and it often starts earlier in life, sometimes in a person’s 30s or 40s. Early signs include numbness, tingling, or burning pain that begins in the feet and slowly moves up the legs and into the hands, along with autonomic symptoms like dizziness on standing, diarrhea or constipation, unintended weight loss, and erectile dysfunction.
The two conditions also often overlap. Many people with hereditary ATTR have both heart and nerve involvement, which is why a new ATTR-CM diagnosis, especially a hereditary one, should prompt a check for neuropathy, and vice versa.
ATTR-CM treatment today: three approved options and a fast-moving landscape
For years, there was exactly one ATTR-CM treatment: tafamidis, approved by the FDA in 2019 as the first therapy shown to reduce mortality and cardiovascular hospitalization in this disease. Tafamidis works by stabilizing the TTR protein in its correct shape, preventing it from breaking apart and forming new amyloid deposits. It doesn't reverse existing damage, but it slows disease progression.
That quickly changed when Acoramidis (Attruby), another oral TTR stabilizer, was approved in November 2024 after the ATTRibute-CM trial showed a significant reduction in death and cardiovascular hospitalization.
Then in March 2025, vutrisiran (Amvuttra) became the third approved ATTR-CM treatment and the first with a fundamentally different mechanism: rather than stabilizing TTR, it's a gene-silencing therapy delivered by injection every three months that reduces production of the protein at its source in the liver. In the HELIOS-B trial, vutrisiran met all ten of its primary and secondary endpoints, including a 28 percent reduction in the combined risk of death and cardiovascular events compared to placebo.
A fourth candidate is close behind: Eplontersen, another TTR gene silencer, is being evaluated for ATTR-CM in the ongoing Phase 3 CARDIO-TTRansform trial.
Because there are no head-to-head trials between tafamidis, acoramidis, and vutrisiran, choosing among them today is often driven by cost, dosing preference, insurance coverage, and individual patient factors rather than clear-cut superiority data. All three carry substantial price tags: tafamidis and acoramidis run over $240,000 per year, and vutrisiran's list price is even higher, though most patients pay little to nothing out of pocket thanks to insurance coverage and manufacturer support programs. Going from zero approved therapies before 2019 to three approved ATTR-CM treatments today, with a fourth in late-stage trials, represents one of the fastest therapeutic turnarounds in a rare cardiac disease.
Why patient registries and real-world data matter for ATTR-CM
Even with three approved therapies now on the market, most of what's known about how ATTR-CM behaves over the long term, across different ages, genotypes, and treatment histories, still comes from clinical trial populations that don't fully reflect the diversity of real-world patients.
If you're living with ATTR-CM, details about your own experience such as how treatment has affected your strength, function, and daily life, what barriers you've faced getting diagnosed or treated, are significant for future research. That kind of real-world information is missing from clinical trials, and what helps move the field forward for the next patient who gets this diagnosis.
About Novellia: Novellia is a patient health platform that helps people consolidate their medical records, understand their health data, and participate in research studies on their own terms. Patients stay in control of their data at every step.
Sources
